`
`October 1 ,1999
`
`Competitive Update: Nothing new to report
`
`Current FTE’s: 3
`
`Monthly Summary: None
`
`The goal of the program is to discover small molecule inhibitors of dipeptidyl peptidase IV (DP4) for
`use in the treatment and prevention of diabetes. Inhibition of DP4 should prevent the degradation of
`GLP—1 and potentiate its action in vivo. BMS-356379 was previously identified as a novel and
`proprietary inhibitor with an inhibitory constant of 28 nM vs pig kindey DP4. Rat oral bioavailability of
`this compound is in progress as well as studies related to in vitro metabolism and P450 inhibition.
`it
`was recently demonstrated that the Caco~2 permeability of this compound is 114 mnfsec, which would
`predict good oral absorption. The cyano substituted cyclopropanated pyrroiidine precursor is currently
`being scaled up for future analoging in this series. In an attempt to uncover other suitable chemotypes
`related to BMS~356379,
`the generation of additional cyclopropanated analogs are in progress.
`In
`contrast to BMS-356379 (a 4,5—fused analog),
`the 2,3—fused anaiog BMS—378736 exhibited only
`marginal activity in the screening assay (20% inhibition @ 10 uM) while the related 3,4-fused analog,
`EMS-378738 (X = H) exhibited significant potency in this screen (80% inhibition @ 10 uM). Ki values
`will be determine shortly. Efforts are currently directed towards generation of the related cyano
`derivative (X = ON) in hopes of further enhancing potency with this chemotype.
`
`Me
`
`H2N
`
`Me
`
`N
`
`‘
`
`0
`
`CN
`
`BMS-356379
`DFL4 screen:
`BLQI R'|ih=|l3§8C_3FH§|0 UM
`
`raj}
`
`Me
`
`HZN
`
`Me
`
`N
`
`_’
`‘If?
`CN
`
`0
`
`3Ms_373735
`DP4 screen:
`20% lnhlb. @ ‘E0 uM
`
`Me
`
`HZN
`
`Me
`
`Nx
`
`0
`
`X
`
`BMS-378738 (X = H)
`DP4 screen:
`30% inhib_ @ 10 "M
`
`Page 1 of 1
`
`Astraleneca Exhibit 2185
`Mylan V. Astraleneca
`IPR2015-013-l0
`
`AstraZeneca Exhibit 2185
`Mylan v. AstraZeneca
`IPR2015-01340
`
`Page 1 of 1